UK consortium led by Paraytec Ltd to develop analytical instrumentation to detect aggregation in biopharmaceutical processing
Professor David Goodall, Chief Scientific Officer at Paraytec commented 'We are delighted to be lead partner in this project. Our award winning ActiPix D100 UV detection technology will play a central role in the novel analytical instrumentation. Our approach will enable simultaneous UV quantification and sizing to allow monomeric species of biopharmaceuticals to be readily distinguished from dimers and aggregates. For bioprocessing companies like Avecia and Lonza, an attraction of this technology is that UV detection is the method of choice for monitoring and quantifying biopharmaceuticals during separation and polishing stages. Thus the ability to gain additional information on size is seen as a significant benefit.'
The development project will take place over the next two years. The project will be followed by commercialization of the instrumentation by Paraytec.
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.